ANI Pharmaceuticals (ANIP) AI Stock Analysis

• Market Cap: $1.41B
• Dividend Yield: N/A
• Average Volume (3M): 275.01K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.33
• Revenue Growth: 30.26%
• EPS Growth: -173.36%
• Country: US
• Employees: 897
• Sector: Healthcare
• Sector Strength: 40
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): 1.70
• Shares Outstanding: 21,651,072
• 10 Day Avg. Volume: 239,494
• 30 Day Avg. Volume: 275,012
• PEG Ratio: 4.77
• Price to Book (P/B): 3.05
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 20.64
• Enterprise Value/Market Cap: 1.12
• Enterprise Value/Revenue: 0.66
• Enterprise Value/Gross Profit: 4.10
• Enterprise Value/Ebitda: 5.21
• 1Y Price Target: $83.50
• Price Target Upside: 28.09% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 5

• Rating: 69 Neutral
• Price Target: $73.00 ▲(11.98%Upside)

ANI Pharmaceuticals' overall stock score is driven by strong revenue growth and effective cash flow management, as well as positive momentum in technical indicators. The increased guidance and strategic investments highlighted in the earnings call further bolster the outlook. However, ongoing profitability challenges and a negative P/E ratio weigh on the valuation, limiting the overall score.

Positive Factors

Commercial Success

ANIP has established itself as a proven commercial execution success story, evidenced by its delivery on its lead asset, Cortrophin Gel, as well as its generics business unit.

Product Growth

Cortrophin Gel continues to grow well, taking market share from Acthar Gel and driving market expansion, including in label indications which Acthar does not have.

Regulatory Approval

The FDA approved an expanded Iluvien label, adding chronic non-infection uveitis affecting the posterior segment to the current DME indication, which came earlier than expected and reflects continued ANI regulatory execution.

Negative Factors

Legal Dispute

ANIP is currently in a legal dispute regarding the rights to receive a 5% royalty from CGON's cretostimogene sales.

Valuation Concerns

The stock is trading at a valuation more suitable for a pure generics company, despite significant contributions and growth from the rare disease portfolio.

ANI Pharmaceuticals Business Overview & Revenue Model

Company Description

ANI Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing, manufacturing, and marketing high-quality branded and generic prescription pharmaceuticals. Operating primarily in the United States, the company offers a diverse portfolio that spans several therapeutic areas, including oncology, hormones, and pain management. ANI Pharmaceuticals is known for its robust manufacturing capabilities and commitment to addressing unmet medical needs.

How the Company Makes Money

ANI Pharmaceuticals generates revenue through the production and sale of both branded and generic prescription drugs. The company's revenue streams are primarily driven by its generic pharmaceutical products, which are sold through a network of wholesalers, distributors, and direct sales channels. ANI also earns income from its branded pharmaceuticals business, which includes specialty products that are marketed directly to healthcare professionals. Additionally, the company engages in strategic partnerships and collaborations to enhance its product offerings and expand its market reach, contributing to its overall earnings.

ANI Pharmaceuticals Financial Statement Overview

Summary

ANI Pharmaceuticals demonstrates robust revenue growth and effective cash flow management, which are positive indicators of operational strength. However, persistent net losses and negative return on equity highlight ongoing profitability challenges. The company maintains a stable balance sheet with manageable leverage, but improving profitability metrics will be crucial for enhancing overall financial health.

Income Statement

ANI Pharmaceuticals has shown a strong revenue growth trajectory, with a significant increase from $208 million in 2020 to $674 million in TTM (Trailing-Twelve-Months) 2025. The gross profit margin remains healthy, indicating efficient cost management. However, the company has struggled with profitability, as evidenced by negative net income in recent periods, impacting the net profit margin adversely.

Balance Sheet

The balance sheet reflects a moderate debt-to-equity ratio, indicating a balanced approach to leverage. The equity ratio suggests a reasonable level of equity financing, but the return on equity is negative due to net losses, highlighting challenges in generating shareholder returns. Overall, the balance sheet is stable but shows room for improvement in profitability.

Cash Flow

Cash flow analysis reveals a positive trend in operating cash flow, with a notable increase in free cash flow over the years. The operating cash flow to net income ratio is strong, indicating effective cash generation relative to accounting profits. However, the company has faced significant investing cash outflows, which could impact future liquidity if not managed carefully.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	674.07M	614.38M	486.82M	316.38M	216.14M	208.47M
Gross Profit	385.28M	364.17M	305.30M	177.60M	115.53M	121.32M
EBITDA	76.14M	79.15M	106.60M	48.07M	-1.68M	29.07M
Net Income	-21.05M	-18.52M	18.78M	-47.90M	-42.60M	-22.55M
Balance Sheet
Total Assets	1.29B	1.28B	904.42M	760.09M	771.60M	461.19M
Cash, Cash Equivalents and Short-Term Investments	149.80M	151.17M	221.12M	48.23M	100.30M	7.86M
Total Debt	317.53M	624.09M	285.67M	286.52M	287.37M	185.69M
Total Liabilities	848.96M	855.17M	446.82M	421.55M	412.86M	265.49M
Stockholders Equity	418.62M	428.53M	457.60M	338.54M	358.74M	195.70M
Cash Flow
Free Cash Flow	68.37M	47.06M	100.45M	-47.66M	-20.32M	-53.05M
Operating Cash Flow	80.74M	64.02M	118.96M	-31.20M	3.32M	15.27M
Investing Cash Flow	-433.50M	-404.72M	-18.51M	-15.74M	-105.48M	-68.32M
Financing Cash Flow	274.76M	264.94M	67.44M	-5.13M	194.59M	-1.44M

ANI Pharmaceuticals Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 65.19
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ANIP, the sentiment is Positive. The current price of 65.19 is above the 20-day moving average (MA) of 65.07, above the 50-day MA of 63.72, and above the 200-day MA of 60.86, indicating a bullish trend. The MACD of 0.56 indicates Positive momentum. The RSI at 53.45 is Neutral, neither overbought nor oversold. The STOCH value of 59.12 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ANIP.

ANI Pharmaceuticals Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COLL	75 Outperform	$1.05B	27.06	19.23%	―	17.17%	-51.97%
SUPN	72 Outperform	$1.90B	30.34	6.32%	―	11.82%	―
ANIP	69 Neutral	$1.41B	―	-5.19%	―	30.26%	-173.36%
AMPH	69 Neutral	$1.03B	7.69	19.90%	―	8.05%	-8.46%
PCRX	60 Neutral	$1.06B	―	-12.27%	―	3.08%	-247.82%
DVAX	53 Neutral	$1.27B	64.45	-10.45%	―	24.76%	-783.38%
Sector *	50 Neutral	AU$2.48B	3.24	-57.47%	2.69%	36.73%	13.67%

ANI Pharmaceuticals Corporate Events

ANI Pharmaceuticals Highlights Financial Performance Amid Challenges

ANI Pharmaceuticals has highlighted its financial performance indicators, emphasizing the importance of adjusted non-GAAP EBITDA and diluted earnings per share as measures of its operating performance. The company is addressing the impact of recent acquisitions, supply chain disruptions, and regulatory challenges on its operations, while also focusing on maintaining profitability and market acceptance of its products.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

ANI Pharmaceuticals Approves Key Proposals at Annual Meeting

ANI Pharmaceuticals, Inc. held its 2025 Annual Meeting of Stockholders on May 22, 2025, where several key proposals were approved. These included amendments to the company’s stock plans and an increase in authorized shares of common stock, reflecting strategic moves to bolster its financial and operational flexibility. The meeting also saw the election of eight directors and the ratification of the appointment of EisnerAmper LLP as the independent registered public accounting firm, indicating a stable governance and financial oversight structure for the upcoming fiscal year.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

ANI Pharmaceuticals Releases May 2025 Financial Presentation

ANI Pharmaceuticals has released a corporate presentation detailing its financial performance and strategic initiatives as of May 2025. The company emphasizes the importance of adjusted non-GAAP financial measures, such as EBITDA and diluted earnings per share, as key indicators of its operating performance. These metrics exclude various non-cash and one-time expenses to provide a clearer picture of the company’s financial health. The presentation also highlights potential risks and uncertainties, including supply chain disruptions and regulatory challenges, which could impact its operations and financial results.

The most recent analyst rating on (ANIP) stock is a Buy with a $94.00 price target. To see the full list of analyst forecasts on ANI Pharmaceuticals stock, see the ANIP Stock Forecast page.

ANI Pharmaceuticals Files Proxy for 2025 Meeting

On April 10, 2025, ANI Pharmaceuticals filed a definitive proxy statement for its 2025 annual meeting of shareholders to consider several proposals, including the approval of the Amended and Restated 2022 Stock Incentive Plan. The company issued a Proxy Supplement to clarify that non-shareholder approved inducement grants are included in the share reserve increase proposal. As of March 24, 2025, ANI Pharmaceuticals had 1,177,800 shares available for future grants under the Stock Plan, which is deemed insufficient to attract and retain key talent. The company emphasizes the importance of the Stock Plan in its compensation strategy, aligning with market standards to motivate and retain employees.